Concepedia

Klemens Hoegenauer

KH

10

Publications

432

Citations

10

H-Index

2003

Active since

Affiliations

Novartis Institutes for BioMedical Research(Current)

Novartis (Switzerland)

Novartis (United States)

Klemens Hoegenauer is an author at Novartis Institutes for BioMedical Research specializing in drug discovery, pharmacology, and medicine.

ORCID

Top concepts

Publications per year

2003–2023

10

Publications

10

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors

Klemens Hoegenauer, Nicolas Soldermann, Frédéric J. Zécri et al. · ACS Medicinal Chemistry Letters · 2017 · 111 citations · Full text

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors

Klemens Hoegenauer, Nicolas Soldermann, Frédéric Stauffer et al. · ACS Medicinal Chemistry Letters · 2016 · 65 citations · Full text

Structural States of RORγt: X‐ray Elucidation of Molecular Mechanisms and Binding Interactions for Natural and Synthetic Compounds

Joerg Kallen, Aude Izaac, C. Be et al. · ChemMedChem · 2017 · 63 citations

Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrations

Christine Guntermann, Alessandro Piaia, Marie-Laure Hamel et al. · JCI Insight · 2017 · 56 citations · Full text

Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase

Klemens Hoegenauer, Shaojian An, Jake Axford et al. · ACS Medicinal Chemistry Letters · 2023 · 28 citations · Full text

Rows per page

1–5 of 10